MOLECULAR INSIGHT PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1997-01-01
- Employees
- 71
- Market Cap
- -
- Website
- http://molecularinsight.com
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
- Conditions
- ParagangliomaPheochromocytoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Registration Number
- NCT02961491
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 99mTc-MIP-1404 InjectionDiagnostic Test: Whole-Body Planar and pelvic SPECT/CT scan
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 531
- Registration Number
- NCT02615067
- Locations
- 🇨🇦
MUHC, Montréal, Quebec, Canada
🇺🇸Louisiana State University Health Science Center, Shreveport, Louisiana, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
- Conditions
- Prostate Cancer
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01667536
- Locations
- 🇨🇿
University Hospital Olomouc, Clinic of Urology, Olomouc, Czech Republic
🇷🇺Moscow Oncology Research Institute n.a. P.A. Hertsen, Moscow, Russian Federation
🇵🇱University Hospital Plzen, Department of Urology, Warsaw, Poland
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01654874
- Locations
- 🇺🇸
New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, United States
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 99mTc MIP 1404
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01615406
- Locations
- 🇺🇸
The University of Texas Health Science Center - Houston, Houston, Texas, United States
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01572701
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Registration Number
- NCT01279785
- Locations
- 🇺🇸
CCR/NCI - Molecular Imaging Program, Bethesda, Maryland, United States
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
- Conditions
- Prostate Cancer
- Interventions
- Radiation: 99mTc MIP 1404Radiation: 99mTc MIP 1405
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01261754
- Locations
- 🇺🇸
New York Presbyterian Hospital - Weill Medical College of Cornell University, New York, New York, United States
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Registration Number
- NCT00992173
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Hospital of LA, Los Angeles, California, United States
🇺🇸UCSF Pediatric Hematology/Oncology, San Francisco, California, United States
A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 111-In capromab pendetide
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00992745
- Locations
- 🇺🇸
West Coast Radiology Centers, Laguna Niguel, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Pacific Coast Imaging, Newport Beach, California, United States